Ocugen to Acquire Ocuphire Pharma for $100M
Ticker: OCGN · Form: 8-K · Filed: Jul 29, 2025 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Jul 29, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, ophthalmology
TL;DR
Ocugen buying Ocuphire for $100M cash/stock, closing Q4 2025.
AI Summary
Ocugen, Inc. announced on July 29, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of Ocuphire Pharma, Inc. for approximately $100 million in cash and stock. This strategic acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could significantly expand Ocugen's pipeline and market presence in the ophthalmology sector, potentially leading to new treatment options for patients.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and the possibility that the acquired company's assets may not perform as expected.
Key Numbers
- $100M — Acquisition Value (Total consideration for Ocuphire Pharma)
- Q4 2025 — Expected Closing (Target timeframe for acquisition completion)
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Acquired Company
- $100 million (dollar_amount) — Acquisition price
- July 29, 2025 (date) — Announcement date
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K is filed to report an Other Event, specifically Ocugen, Inc.'s entry into a definitive agreement to acquire Ocuphire Pharma, Inc.
What is the total value of the proposed acquisition?
The definitive agreement is for approximately $100 million in cash and stock.
When is the acquisition expected to be completed?
The acquisition is expected to close in the fourth quarter of 2025.
What are the conditions for the acquisition to close?
The closing is subject to customary closing conditions.
What is Ocugen, Inc.'s principal executive office address?
Ocugen, Inc.'s principal executive offices are located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Ocugen, Inc. (OCGN).